Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Grou
about
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
P2860
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Grou
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dose-dense FEC followed by doc ...... ellenic Oncology Research Grou
@en
type
label
Dose-dense FEC followed by doc ...... ellenic Oncology Research Grou
@en
prefLabel
Dose-dense FEC followed by doc ...... ellenic Oncology Research Grou
@en
P2093
P2860
P356
P1433
P1476
Dose-dense FEC followed by doc ...... ellenic Oncology Research Grou
@en
P2093
A Athanasiadis
Breast Cancer Investigators of ...... h Group (HORG), Athens, Greece
D Mavroudis
E Saloustros
I Boukovinas
N Kentepozidis
P Katsaounis
P2860
P304
P356
10.1093/ANNONC/MDW274
P577
2016-08-08T00:00:00Z